浏览全部资源
扫码关注微信
1.陕西中医药大学 药学院,陕西 咸阳 712046
2.中国中医科学院 中药研究所 中药质量控制技术国家工程实验室,北京 100700
冯霞霞,硕士,从事中药质量评价研究,E-mail:1433041096@qq.com
刘晓谦,副研究员,从事中药制剂与质量控制,Tel/Fax:010-84017310,E-mail:lianyu1127@126.com
王智民,研究员,从事中药药效物质基础及质量评价研究,Tel/Fax:010-84014128,E-mail:zhm123@263.net
纸质出版日期:2021-01-20,
网络出版日期:2020-05-21,
收稿日期:2020-04-01,
扫 描 看 全 文
冯霞霞,易红,闫利华等.从六味地黄制剂多剂型间的质量差异探索中成药质量控制[J].中国实验方剂学杂志,2021,27(02):138-145.
FENG Xia-xia,YI Hong,YAN Li-hua,et al.Discussion for Quality Control of Chinese Patent Drugs from Quality Difference Among Different Dosage Forms of Liuwei Dihuang Preparations[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):138-145.
冯霞霞,易红,闫利华等.从六味地黄制剂多剂型间的质量差异探索中成药质量控制[J].中国实验方剂学杂志,2021,27(02):138-145. DOI: 10.13422/j.cnki.syfjx.20201556.
FENG Xia-xia,YI Hong,YAN Li-hua,et al.Discussion for Quality Control of Chinese Patent Drugs from Quality Difference Among Different Dosage Forms of Liuwei Dihuang Preparations[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):138-145. DOI: 10.13422/j.cnki.syfjx.20201556.
目的
2
通过对市售不同厂家的六味地黄制剂的质量进行全面评估、分析,并结合生产工艺等因素,探讨六味地黄制剂质量控制中的关键因素,为提升六味地黄方质量控制水平提供参考。
方法
2
在HPLC测定六味地黄方中3个现行质量控制指标(莫诺苷、马钱苷、丹皮酚)基础上,参照2015年版《中国药典》所记载的检测方法,以乙腈(A)-0.3%磷酸水溶液(B)为流动相梯度洗脱(0~5 min,5%~8%A;5~20 min,8%A;20~35 min,8%~20%A;35~45 min,20%~60%A;45~55 min,60%A),丹皮酚检测波长274 nm,莫诺苷、马钱苷检测波长均为240 nm。对来源于不同厂家的5个剂型(大蜜丸、水蜜丸、浓缩丸、胶囊、软胶囊)的六味地黄产品中指标成分进行含量测定并进行统计分析;结合数据结果和生产工艺的实际情况,挖掘潜在的质量控制弱点,并探讨其质量控制策略。
结果
2
128批六味地黄产品的指标成分含量测定结果均符合2015年版《中国药典》的相关规定,但部分剂型的现行标准的含量限度存在不合理之处,如水蜜丸与大蜜丸,其生产工艺一致,但是日服生药量大蜜丸约为水蜜丸的2倍(分别为15.00,8.57 g),但其指标成分的日服含量限度却完全一样。
结论
2
对于中成药工艺无质的改变的剂型间含量测定指标及其限度,建议应尽可能保持一致,有利于多剂型产品纵向和横向的质量一致性对比。中成药质量标准的研究应深入探索质量标准的赋存特征,充分尊重药材、饮片质量属性传递规律和中成药生产过程规律。
Objective
2
Through comprehensive evaluation and analysis of the quality of Liuwei Dihuang (LWDH) preparations from different manufacturers and combining factors such as production technology, the key factors in the quality control of LWDH preparations are explored to provide a reference for improving the quality control level of LWDH preparations.
Method
2
Morroniside, loganin and paeonol as quality control markers of LWDH products were determined by high performance liquid chromatography (HPLC), the mobile phase was acetonitrile (A) -0.3% phosphoric acid aqueous solution (B) for gradient elution (0-5 min, 5%-8%A; 5-20 min, 8%A; 20-35 min, 8%-20%A; 35-45 min, 20%-60%A; 45-55 min, 60%A), the detection wavelength of paeonol was at 274 nm, and the detection wavelengths of morroniside and loganin were at 240 nm. The quality characteristics of LWDH preparations with different dosage forms (big candied pills, water-honeyed pills, concentrated pills, hard capsules and soft capsules) from different manufacturers were analyzed. Combined these results with their actual production processes, the key-points of quality control in the whole production process were discussed.
Result
2
The contents of three index ingredients in 128 batches of LWDH preparations were all in conformity with the standards of the 2015 edition of
Chinese Pharmacopoeia
, however, the content limit of some dosage forms in the current standard was unreasonable. For example, although the daily dose of crude drugs for big candied pills were almost twice the dose of water- honeyed pills (15.00, 8.57 g, respectively), they got exactly the same daily limits of the contents for both the quality markers. What′s more, these two formulations had the same process, so the differences between the process obviously could not be the reason of these differences.
Conclusion
2
It is recommended that for the products with different dosage forms should have a similar content limits, if there are no obvious distinctions between their production processes. Which may benefit the quality control of the products with multi-dosage forms. The research on the quality standards of proprietary Chinese medicines should deeply study the existing characteristics of the quality standards, and fully respect the laws of the quality attributes of traditional Chinese medicines and the rules of the production process of Chinese patent medicines.
六味地黄制剂莫诺苷马钱苷丹皮酚含量测定高效液相色谱法质量控制
Liuwei Dihuang preparationsmorronisideloganinpaeonolcontent determinationhigh performance liquid chromatography (HPLC)quality control
国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2015:28,172,707.
蔡惠芳,谭元生,何泽云,等.六味地黄丸对大鼠5/6肾切除肾功能的影响[J].湖南中医药大学学报,2007,27(2):17-19.
吴炜景,李立平, 赵亚刚.六味地黄丸免疫调节作用的研究进展[J].现代中西医结合杂志,2011,20(32):4080-4082.
刘博.六味地黄丸免疫调节作用进展[J].医药导报,2010,29(8):1051-1053.
郑里翔,林栋美,刘红宁,等.滋阴经方经TGF-β途径抑制小鼠自发乳腺癌生长的机理[J].中成药,2011,33(10):1793-1795.
饶斌,谢斌,余功,等.滋阴方六味地黄丸抗肿瘤研究进展[J].江西中医药大学学报,2014,26(1):84-87.
朱坤杰,孙建宁.六味地黄丸对D-半乳糖所致衰老大鼠学习记忆的改善作用及机理[J].中国实验方剂学杂志,2006,12(8):44-46.
张璐,方朝晖.六味地黄丸治疗糖尿病研究进展[J].中医药临床杂志,2018,30(12):162-165.
韩旭华,王世民,张乃钲.六味地黄汤对骨质疏松大鼠骨生物力学特征和钙磷含量的影响[J].中药药理与临床,2002,8(3):1-2.
温建丽,李艳红.HPLC法测定六味地黄胶囊中酒萸肉的含量[J].科学之友,2010(9):15-16.
赵洪芝,孟宪生,叶挺祥,等.双波长融合HPLC测定六味地黄丸中马钱苷、丹皮酚的含量[J].中国中药杂志,2008,33(19):2182-2184.
张乔,俞洋洋,王勤辉,等.六味地黄制剂多类型成分快速分析和“一测多评”方法建立[J].中国实验方剂学杂志,2014,20(6):81-86.
水彩红,曹红.HPLC法测定山茱萸药材及六味地黄胶囊中马钱苷的含量[J].中国药品标准,2005,6(4):17-20.
谢宝刚,钟琳,朱思琪,等.HPLC-UV法同时测定六味地黄制剂中丹皮酚与熊果酸[J].中成药,2013,35(5):970-973.
王灵霞,朱东亮,柴逸峰.高效液相色谱法同时测定3种不同剂型六味地黄丸中4种成分的含量[J].药学实践杂志,2013,31(4):296-299.
0
浏览量
11
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构